Curanex Pharmaceuticals Inc is a US-based company operating in Pharmaceuticals industry. The company is headquartered in Jericho, New York. The company went IPO on 2025-08-26. Curanex Pharmaceuticals Inc is a developmental stage pharmaceutical company. The firm is engaged in discovering, developing, and commercializing botanical drugs to treat patients suffering from inflammatory diseases and to develop therapies that offer potential benefits to patients with unmet clinical needs in various fields, such as autoimmune diseases, metabolic diseases and viral infections. Its lead candidate, Phyto-N, is a botanical extract from a single plant with anti-inflammatory properties that act via multiple targets and mechanisms. Its drug development pipelines encompass six various therapeutic areas: ulcerative colitis, atopic dermatitis, COVID-19, diabetes, NAFLD, and gout. Phyto-N is being developed as an orally administered alternative for patients with moderate to severe ulcerative colitis, aiming to address limitations of current treatments. The firm's two botanical drugs include Veregen (sinecatechins) and Fulyzaq/Mytesi (crofelemer).
Follow-Up Questions
Who is the CEO of Curanex Pharmaceuticals Inc?
Mr. Jun Liu is the President of Curanex Pharmaceuticals Inc, joining the firm since 2024.
What is the price performance of CURX stock?
The current price of CURX is $0.6461, it has decreased 3.88% in the last trading day.
What are the primary business themes or industries for Curanex Pharmaceuticals Inc?
Curanex Pharmaceuticals Inc belongs to Pharmaceuticals industry and the sector is Health Care
What is Curanex Pharmaceuticals Inc market cap?
Curanex Pharmaceuticals Inc's current market cap is $18.3M
